InspireMD Q3 2022 revenue up 33.6% to $1.43M; net loss widens to $4.5M

InspireMD, Inc.

2023-Q3 EPS reported -$1.75 revenue$4,145,000

CGuard revenue grew 38.8% YoY to $1,430,836; total revenue $1,431,000 (+33.6%).
Net loss of $4.5M ($0.58/share) vs $4.1M ($0.53) in Q3 2021; operating expenses up 20.7%.
Cash and equivalents $21.0M at Sep 30, 2022, down from $34.0M at Dec 31, 2021.
CE Mark under MDR expires Nov 12; company preparing inventory for potential recertification delay.
C-Guardian US IDE trial on track with 24 sites; enrollment completion expected by end of Q1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

InspireMD, Inc. reported financial results for three and nine months ended September 30, 2022.

Period: three and nine months ended September 30, 2022
Result: reported results

Exact text from the filing

On November 8, 2022, InspireMD, Inc. issued a press release announcing its financial and operating results and recent highlights for the three and nine months ended September 30, 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

InspireMD, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-030876

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.